BoomRay Pharmaceuticals Co., Ltd. is a clinical-stage biotech focusing on delivering innovative radionuclide Drug Conjugates (RDC) for precise tumor diagnosis and treatment. Currently, BoomRay has multiple clinical-stage products. In 2022, BoomRay completed nearly RMB300 million in Series A financing. At present, BoomRay has a number of proprietary diagnostic and therapeutic radionuclide drugs under research, with independent intellectual property rights. Headquartered in Suzhou, BoomRay has also established business departments for new drug discovery, clinical translations, and registration in Beijing and Shanghai. The company has a management team led by overseas high-profile talents with rich backgrounds in the nuclear medicine industry and experience in drug design and translation...